Gyre Therapeutics, Inc. insider trading
Every open-market purchase and sale by Gyre Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Gyre Therapeutics, Inc.’s insiders pay?
From January 5, 2010 to June 22, 2026, 28 insiders reported 12 open-market purchases and 65 sales not made under a pre-set plan in Gyre Therapeutics, Inc. Twelve months after each purchase was reported, the shares were −35.7% against the S&P 500 on average (median −34.5%), over 3 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −49.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 14, 2013 into $8,942 by November 2, 2026, −0.8% a year. It held shares 15% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $19,882 (+5.2% a year), and held throughout $57,539 (+13.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Caldwell William S | SVP - Drug Discovery and Dev. | 0 | — | — | 8 | −38.7% (8) | April 4, 2011 |
| Ye Weiguo | Chief Operating Officer | 0 | — | — | 8 | — | June 22, 2026 |
| Dunbar Geoffrey C | SVP, Clin. Dev. & Reg. Affairs | 0 | — | — | 7 | −44.8% (7) | December 21, 2010 |
| Hodges Mauri K | VP Fin + Corp Sys & Controller | 0 | — | — | 7 | −65.6% (7) | March 11, 2011 |
| Hicks Karen A | VP Human Resources | 0 | — | — | 5 | −60.6% (5) | March 3, 2011 |
| Musso Alan A | SVP, CFO & Treasurer | 0 | — | — | 5 | −54.1% (5) | June 8, 2011 |
| Richard John P | Director | 1 | — | — | 4 | −71.9% (4) | June 11, 2012 |
| Bencherif Merouane | SVP, Preclinical Research | 0 | — | — | 4 | −29.6% (4) | January 20, 2011 |
| Brown Julia R | Director | 1 | −46.5% (1) | 0% | 3 | −44.3% (3) | May 13, 2013 |
| Dunton Alan W | Director | 0 | — | — | 3 | −21.8% (3) | August 3, 2010 |
| Brennan Jeffrey P | SVP - Bus. & Commercial Dev. | 0 | — | — | 2 | −74.8% (2) | March 3, 2011 |
| Hill Stephen A | President and CEO | 2 | — | — | 0 | — | December 18, 2015 |
| Lampert Mark N | 10% owner | 2 | — | — | 0 | — | November 19, 2012 |
| Barrett M James | 10% owner | 0 | — | — | 1 | −71.9% (1) | December 5, 2013 |
| Barris Peter J and related entities | 10% owner | 0 | — | — | 1 | −72.2% (1) | November 22, 2013 |
| Biotechnology Value Fund L P | 10% owner | 1 | — | — | 0 | — | November 9, 2012 |
| Blixt Charles A | Director | 0 | — | — | 1 | −71.3% (1) | November 18, 2010 |
| Burrill Steven | Director | 0 | — | — | 1 | −83.0% (1) | May 12, 2011 |
| Deerfield Management Company, L.P. | 10% owner | 0 | — | — | 1 | −69.7% (1) | March 8, 2018 |
| Lawlor Augustine | Director | 0 | — | — | 1 | −25.4% (1) | February 25, 2020 |
| Levy Howard | Chief Medical Officer | 1 | — | — | 0 | — | March 17, 2020 |
| Ling Geoffrey M.D. | Director | 1 | −26.0% (1) | 0% | 0 | — | February 27, 2020 |
| Payne Fletcher | Chief Financial Officer | 1 | — | — | 0 | — | December 18, 2015 |
| Skaletsky Mark B | Director | 0 | — | — | 1 | −71.3% (1) | November 18, 2010 |
| Snyderman Ralph | Director | 0 | — | — | 1 | +13.5% (1) | February 18, 2010 |
| Usman Nassim | President & CEO | 1 | — | — | 0 | — | March 13, 2020 |
| Williams Eddie | Director | 1 | −34.5% (1) | 0% | 0 | — | March 4, 2020 |
| Zorn Peter A | VP, Lg Affrs, GC and Secrtary | 0 | — | — | 1 | +21.9% (1) | January 5, 2010 |
When several insiders traded Gyre Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Gyre Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −12.5% against the index. After 2 selling crowds, −2.9%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 31, 2013 | 2 buying | −9.5% | −12.5% | −52.2% |
| November 30, 2010 | 5 selling | +29.1% | −8.0% | −69.2% |
| April 30, 2010 | 3 selling | −2.4% | +2.2% | −15.5% |